Ad is loading...
CVGRX
Price
$45.90
Change
-$1.01 (-2.15%)
Updated
Nov 15 closing price
GFACX
Price
$69.11
Change
-$1.16 (-1.65%)
Updated
Nov 15 closing price
Ad is loading...

CVGRX vs GFACX

Header iconCVGRX vs GFACX Comparison
Open Charts CVGRX vs GFACXBanner chart's image
Calamos Growth A
Price$45.90
Change-$1.01 (-2.15%)
VolumeN/A
CapitalizationN/A
American Funds Growth Fund of Amer C
Price$69.11
Change-$1.16 (-1.65%)
VolumeN/A
CapitalizationN/A
CVGRX vs GFACX Comparison Chart
Loading...
View a ticker or compare two or three
VS
CVGRX vs. GFACX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CVGRX is a StrongBuy and GFACX is a StrongBuy.

FUNDAMENTALS
Fundamentals
GFACX has more cash in the bank: 298B vs. CVGRX (1.59B). CVGRX (0.00) and GFACX (0.00) have matching dividends . CVGRX was incepted earlier than GFACX: CVGRX (34 years) vs GFACX (24 years). CVGRX is a more actively managed with annual turnover of: 57.00 vs. GFACX (31.00). GFACX has a lower initial minimum investment than CVGRX: GFACX (250) vs CVGRX (2500). CVGRX annual gain was more profitable for investors over the last year : 29.26 vs. GFACX (25.86). GFACX return over 5 years is better than : 44.67 vs. CVGRX (37.84).
CVGRXGFACXCVGRX / GFACX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence34 years24 years-
Gain YTD28.53525.655111%
Front LoadN/AN/A-
Min. Initial Investment25002501,000%
Min. Initial Investment IRAN/AN/A-
Net Assets1.59B298B1%
Annual Yield % from dividends0.000.00-
Returns for 1 year29.2625.86113%
Returns for 3 years-2.96-8.3935%
Returns for 5 years37.8444.6785%
Returns for 10 years-10.0454.23-19%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ENLC15.490.16
+1.04%
Enlink Midstream LLC
PRLD1.040.01
+0.97%
Prelude Therapeutics
RELX44.45-1.50
-3.26%
Relx PLC
AKBA1.79-0.07
-3.76%
Akebia Therapeutics
VRDN20.14-1.50
-6.93%
Viridian Therapeutics